Intraday Performance and Price Movement
On 24 Apr 2026, Sun Pharmaceutical Industries Ltd’s share price declined sharply, hitting an intraday low of Rs 1,626.10, down 3.2% from the prior session. The stock closed the day with a loss of 3.11%, underperforming the Pharmaceuticals & Biotechnology sector by 2.04%. This decline marked a reversal after two consecutive days of gains, signalling a shift in short-term momentum.
The stock’s closing price remains just 4.85% above its 52-week low of Rs 1,547.25, indicating proximity to a significant support level. The downward movement was accompanied by the stock trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring the prevailing weakness in price trends.
Market Context and Broader Indices
The decline in Sun Pharma’s shares coincided with a broadly negative market environment. The Sensex opened 180.20 points lower and extended losses to close at 76,831.61, down 652.19 points or 1.07%. The benchmark index is currently trading below its 50-day moving average, which itself is positioned beneath the 200-day moving average, a configuration often interpreted as bearish.
Sun Pharmaceutical Industries Ltd’s one-day performance of -3.19% notably lagged the Sensex’s -1.09% decline, reflecting heightened selling pressure on the stock relative to the broader market. Over the past week, the stock has fallen 2.92%, slightly underperforming the Sensex’s 2.14% loss. The one-month trend is more pronounced, with Sun Pharma down 7.22% while the Sensex gained 3.71%, highlighting sector-specific or stock-specific headwinds.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Technical Indicators and Trend Analysis
Technical signals for Sun Pharmaceutical Industries Ltd present a mixed but predominantly cautious picture. The daily moving averages indicate a mildly bullish stance; however, the weekly and monthly technicals lean towards bearish or mildly bearish. Specifically, the weekly MACD is bearish, while the monthly MACD is mildly bearish. Bollinger Bands suggest mild bearishness on a weekly basis and bearishness monthly, signalling increased volatility and downward pressure.
The stock’s Relative Strength Index (RSI) on weekly and monthly charts shows no clear signal, indicating a neutral momentum stance. The KST indicator is bullish weekly but mildly bearish monthly, reflecting short-term strength amid longer-term caution. Dow Theory assessments are mildly bearish weekly but mildly bullish monthly, further illustrating the nuanced technical backdrop.
On balance, the technical environment suggests that while short-term price action is under pressure, there remains some underlying resilience in the medium term. The On-Balance Volume (OBV) indicator is mildly bearish weekly but mildly bullish monthly, indicating mixed volume trends.
Performance Relative to Benchmarks
Sun Pharmaceutical Industries Ltd’s longer-term performance remains robust despite recent weakness. Over three years, the stock has appreciated 66.08%, significantly outperforming the Sensex’s 27.90% gain. Over five years, the stock’s return of 155.05% dwarfs the Sensex’s 60.44%. However, the 10-year performance of 98.29% trails the Sensex’s 197.29%, reflecting varying market cycles.
Year-to-date, the stock has declined 5.43%, outperforming the Sensex’s sharper 9.86% fall, indicating relative resilience in a challenging market environment. Nonetheless, the recent underperformance over one month and one week highlights immediate pressures on the stock price.
Why settle for Sun Pharmaceutical Industries Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology large-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Rating Update
Sun Pharmaceutical Industries Ltd currently holds a Mojo Score of 62.0, categorised as a Hold. This represents a downgrade from a previous Buy rating issued on 21 Apr 2026. The downgrade reflects the recent price pressures and technical deterioration observed in the stock’s performance.
The company is classified as a large-cap within the Pharmaceuticals & Biotechnology sector and industry, with a market cap grade consistent with its size and market presence. The downgrade in rating aligns with the stock’s recent underperformance relative to sector and market benchmarks.
Summary of Price and Trend Metrics
To summarise, Sun Pharmaceutical Industries Ltd’s share price is currently facing immediate downward pressure, trading below all major moving averages and near its 52-week low. The stock’s recent decline of 3.11% on 24 Apr 2026 contrasts with the broader market’s 1.07% fall, indicating relative weakness. Technical indicators present a cautious outlook with mixed signals, while the Mojo rating downgrade to Hold reflects the current market sentiment.
Investors observing the stock should note the proximity to key support levels and the broader market’s bearish tone, as reflected in the Sensex’s positioning below critical moving averages. The stock’s longer-term performance remains strong, but near-term price action is subdued amid prevailing market conditions.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
